Is Fibrobiologics Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Fibrobiologics Inc (FBLG) is currently classified as NOT HALAL as of February 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Fibrobiologics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Fibrobiologics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Fibrobiologics Inc?

Muslim investors may consider investing in Fibrobiologics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Fibrobiologics Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Fibrobiologics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Fibrobiologics Inc updated?

The Shariah compliance status of Fibrobiologics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Fibrobiologics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Fibrobiologics Inc?

You can check the latest Shariah compliance status of Fibrobiologics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

FBLG Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: February 26, 2026

Report Source: 2025 Annual Report

Analyst's Ratings for Fibrobiologics Inc (FBLG)

Based on 9 analysts giving stock ratings to Fibrobiologics Inc in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Fibrobiologics Inc. Stock Analysis FBLG

United States Health Care Nano Cap Report: 2025 Annual

FibroBiologics, Inc. engages in the development and commercialization of cell therapies. The company is headquartered in Houston, Texas and currently employs 15 full-time employees. The company went IPO on 2024-01-31. The firm is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. The company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.

Key Statistics of Fibrobiologics Inc (FBLG)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$1.01$1.11

Today's Open

$1.09

Volume

122.18K

P/E Ratio (TTM)

52 Week Range

$0.95$22.60

Market Cap

6.93M

Avg. Volume

384.29K

Dividend Yield

Financial Metrics & Statements of Fibrobiologics Inc (FBLG)

FAQ's for Fibrobiologics Inc (FBLG)

According to Musaffa’s Shariah screening methodology, Fibrobiologics Inc (FBLG) is currently classified as NOT HALAL as of February 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.